Predicted protein targets (top 17)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | NR1D1 | P20393 | 1/20 | 0.40 |
| ▸ | KCNJ1 | P48048 | 8/20 | 0.39 |
| ▸ | KCNH2 | Q12809 | 7/20 | 0.39 |
| ▸ | SIGMAR1 | Q99720 | 2/20 | 0.38 |
| ▸ | OPRK1 | P41145 | 1/20 | 0.36 |
| ▸ | L3MBTL1 | Q9Y468 | 1/20 | 0.35 |
| ▸ | ALDH1A1 | P00352 | 1/20 | 0.35 |
| ▸ | LMNA | P02545 | 1/20 | 0.35 |
| ▸ | MAPT | P10636 | 1/20 | 0.35 |
| ▸ | S1PR1 | P21453 | 1/20 | 0.35 |
| ▸ | KDM4E | B2RXH2 | 1/20 | 0.35 |
| ▸ | NPC1 | O15118 | 1/20 | 0.35 |
| ▸ | NR2F2 | P24468 | 1/20 | 0.35 |
| ▸ | MAPK1 | P28482 | 1/20 | 0.35 |
| ▸ | RAB9A | P51151 | 1/20 | 0.35 |
| ▸ | SMN1; SMN2 | Q16637 | 1/20 | 0.35 |
| ▸ | POLB | P06746 | 1/20 | 0.35 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL3773796 | 0.97 | NR1D1 (0.42) | NR1D1KCNJ1KCNH2SIGMAR1OPRK1 | |
| SCHEMBL13014059 | 0.92 | NR1D1 (0.39) | NR1D1KCNJ1KCNH2SIGMAR1OPRK1 | |
| SCHEMBL21448717 | 0.91 | NR1D1 (0.39) | NR1D1KCNJ1KCNH2SIGMAR1NPC1 | |
| SCHEMBL17986224 | 0.90 | NR1D1 (0.41) | NR1D1KCNJ1KCNH2SIGMAR1NPC1 | |
| SCHEMBL17986064 | 0.90 | NR1D1 (0.41) | NR1D1KCNJ1KCNH2SIGMAR1NPC1 | |
| SCHEMBL13014380 | 0.90 | ATM (0.42) | KCNJ1KCNH2SIGMAR1OPRK1L3MBTL1 | |
| SCHEMBL18021199 | 0.88 | KCNJ1 (0.39) | NR1D1KCNJ1KCNH2SIGMAR1NPC1 | |
| SCHEMBL21448716 | 0.87 | NR1D1 (0.41) | NR1D1KCNJ1KCNH2SIGMAR1 | |
| SCHEMBL17986065 | 0.86 | NR1D1 (0.43) | NR1D1KCNJ1KCNH2SIGMAR1NPC1 | |
| SCHEMBL3249763 | 0.86 | KCNJ1 (0.46) | KCNJ1KCNH2SIGMAR1OPRK1S1PR1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 6 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-10556873-B2 | Bimodal ligands with macrocyclic and acyclic binding moieties, complexes and compositions thereof, and methods of using | ILLINOIS INSTITUTE OF TECHNOLOGY (US) | 2020-02-11 | — | — | US | disclosed |
| US-10189803-B2 | Synthesis of therapeutic and diagnostic drugs centered on regioselective and stereoselective ring opening of aziridinium ions | ILLINOIS INSTITUTE OF TECHNOLOGY (US) | 2019-01-29 | — | — | US | disclosed |
| US-20170008863-A1 | SYNTHESIS OF THERAPEUTIC AND DIAGNOSTIC DRUGS CENTERED ON REGIOSELECTIVE AND STEREOSELECTIVE RING OPENING OF AZIRIDINIUM IONS | CHONG, HYUN-SOON, PHD | 2017-01-12 | — | — | US | disclosed |
| US-20160052894-A1 | BIMODAL LIGANDS WITH MACROCYCLIC AND ACYCLIC BINDING MOIETIES, COMPLEXES AND COMPOSITIONS THEREOF, AND METHODS OF USING | CHONG, HYUN-SOON, PHD | 2016-02-25 | — | — | US | disclosed |
| US-9115094-B2 | Bimodal ligands with macrocyclic and acyclic binding moieties, complexes and compositions thereof, and methods of using | THE UNITED STATES OF AMERICA, NATIONAL INSTITUTES OF HEALTH (NIH), U.S. DEPT. OF HEALTH AND HUMAN SERVICES (DHHS) (US) | 2015-08-25 | — | — | US | disclosed |
| US-20100322855-A1 | Bimodal ligands with macrocyclic and acyclic binding moieties, complexes and compositions thereof, and methods of using | ILLINOIS INSTITUTE OF TECHNOLOGY (US) | 2010-12-23 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (5 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-10556873-B2 | Bimodal ligands with macrocyclic and acyclic binding moieties, complexes and compositions thereof, and methods of using | UACA, CLTC, CLTA | NR1D1 1241/4885KCNJ1 4733/4885KCNH2 3435/4885 |
| US-20160052894-A1 | BIMODAL LIGANDS WITH MACROCYCLIC AND ACYCLIC BINDING MOIETIES, COMPLEXES AND COMPOSITIONS THEREOF, AND METHODS OF USING | UACA, CLTC, CLTA | NR1D1 1241/4885KCNJ1 4733/4885KCNH2 3435/4885 |
| US-20170008863-A1 | SYNTHESIS OF THERAPEUTIC AND DIAGNOSTIC DRUGS CENTERED ON REGIOSELECTIVE AND STEREOSELECTIVE RING OPENING OF AZIRIDINIUM IONS | AZI2, ABL1, DHPS | NR1D1 3360/4885KCNJ1 296/4885KCNH2 710/4885 |
| US-10189803-B2 | Synthesis of therapeutic and diagnostic drugs centered on regioselective and stereoselective ring opening of aziridinium ions | AZI2, ABL1, DHPS | NR1D1 3360/4885KCNJ1 296/4885KCNH2 710/4885 |
| US-20100322855-A1 | Bimodal ligands with macrocyclic and acyclic binding moieties, complexes and compositions thereof, and methods of using | UACA, CLTC, PKD1 | NR1D1 1424/4885KCNJ1 4684/4885KCNH2 3525/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.